+ Follow ROLF KREBS Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 83359
[Title] => Partnership on COPD treatment bared
[Summary] => Boehringer Ingelheim and Pfizer Inc. have entered into a long-term worldwide agreement to jointly market Spiriva (tiotropium), a novel once-a-day inhaled treatment for Chronic Obstructive Pulmonary Disease (COPD), which includes chronic bronchitis and emphysema.
Boehringer Ingelheim has filed for marketing approval with regulatory authorities in Europe, where Spiriva could be available as early as mid-2002.
A new drug application for Spiriva is anticipated to be filed with the US Food and Drug Administration later this year.
[DatePublished] => 2001-04-23 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
ROLF KREBS
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 83359
[Title] => Partnership on COPD treatment bared
[Summary] => Boehringer Ingelheim and Pfizer Inc. have entered into a long-term worldwide agreement to jointly market Spiriva (tiotropium), a novel once-a-day inhaled treatment for Chronic Obstructive Pulmonary Disease (COPD), which includes chronic bronchitis and emphysema.
Boehringer Ingelheim has filed for marketing approval with regulatory authorities in Europe, where Spiriva could be available as early as mid-2002.
A new drug application for Spiriva is anticipated to be filed with the US Food and Drug Administration later this year.
[DatePublished] => 2001-04-23 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
